A chronic oral reference dose for hexavalent chromium-induced intestinal cancer

Journal of Applied Toxicology

Volumn 34, Issue 5, 2014, Pages 525-536

  Thompson, Chad M ^a   Kirman, Christopher R ^b   Proctor, Deborah M ^c   Haws, Laurie C ^d   Suh, Mina ^c   Hays, Sean M ^b   Hixon, J Gregory ^d   Harris, Mark A ^a  

^a ToxStrategies Inc   (United States)

^b LLP   (United States)

^c ToxStrategies Inc   (United States)

^d ToxStrategies Inc   (United States)

Author keywords

Benchmark dose (BMD) modeling; Cancer reference dose (RfD); Constrained nonlinear regression; Hexavalent chromium Cr(VI); Intestinal cancer; Mode of action; Risk assessment

Indexed keywords

CHROMIUM; DICHROMATE SODIUM; DRINKING WATER;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DUODENUM; EPITHELIUM HYPERPLASIA; FEMALE; HAZARD ASSESSMENT; ILEUM; INTESTINE CANCER; INTESTINE INJURY; JEJUNUM; LONG TERM EXPOSURE; MALE; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; SAFETY; SMALL INTESTINE CARCINOMA; TOXICOKINETICS; UNCERTAINTY;

MUS; RATTUS;

BENCHMARK DOSE (BMD) MODELING; CANCER REFERENCE DOSE (RFD); CONSTRAINED NONLINEAR REGRESSION; HEXAVALENT CHROMIUM CR(VI); INTESTINAL CANCER; MODE OF ACTION; RISK ASSESSMENT;

ANIMALS; CARCINOGENICITY TESTS; CHROMIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING WATER; FEMALE; HUMANS; HYPERPLASIA; INTESTINAL NEOPLASMS; MALE; MICE; MODELS, BIOLOGICAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; REFERENCE STANDARDS; SEX FACTORS; TOXICITY TESTS, CHRONIC; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY; WATER POLLUTANTS, CHEMICAL;

EID: 84897065687     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2907     Document Type: Article

References (44)

1. Ames BN, Shigenaga MK, Gold LS. 1993. DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ. Health Perspect. 101(Suppl 5): 35-44.
2. Atanassoff PG, Brull SJ, Weiss BM, Landefeld K, Alon E, Rohling R. 1995. The time course of gastric pH changes induced by omeprazole and ranitidine: a 24-hour dose-response study. Anesth. Analg. 80: 975-979.
3. AWWA. 2004. Occurrence Survey of Boron and Hexavalent Chromium. American Water Works Association Research Foundation: Denver, CO.
4. Barraj L, Scrafford C, Lantz J, Daniels C, Mihlan G. 2009. Within-day drinking water consumption patterns: results from a drinking water consumption survey. J. Expo. Sci. Environ. Epidemiol. 19: 382-395.
5. Boobis AR, Daston GP, Preston RJ, Olin SS. 2009. Application of key events analysis to chemical carcinogens and noncarcinogens. Crit. Rev. Food Sci. Nutr. 49: 690-707.
6. CDPH 2011. Chromium-6 in Drinking Water: An overview of sampling results. California Department of Public Health.
7. Cohen SM. 2010. An enhanced thirteen-week bioassay as an alternative for screening for carcinogenesis factors. Asian Pacific J Cancer Prevent APJCP 11: 15-17.
8. De Flora S, Badolati GS, Serra D, Picciotto A, Magnolia MR, Savarino V. 1987. Circadian reduction of chromium in the gastric environment. Mutat. Res. 192: 169-174.
9. De Flora S, Camoirano A, Bagnasco M, Bennicelli C, Corbett GE, Kerger BD. 1997. Estimates of the chromium(VI) reducing capacity in human body compartments as a mechanism for attenuating its potential toxicity and carcinogenicity. Carcinogenesis 18: 531-537.
10. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. 2008. Do acid-lowering agents affect vitamin B12 status in older adults? J. Am. Med. Dir. Assoc. 9: 162-167.
11. Febel H, Szegedi B, Huszar S. 2001. Absorption of inorganic, trivalent and hexavalent chromium following oral and intrajejunal doses in rats. Acta Vet. Hung. 49: 203-209.
12. Gatto NM, Kelsh MA, Mai DH, Suh M, Proctor DM. 2010. Occupational exposure to hexavalent chromium and cancers of the gastrointestinal tract: a meta-analysis. Cancer Epidemiol. 34: 388-399.
13. Gaylor DW. 2005. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? Regul. Toxicol. Pharmacol. 41: 128-133.
14. Glaser U, Hochrainer D, Kloppel H, Oldiges H. 1986. Carcinogenicity of sodium dichromate and chromium (VI/III) oxide aerosols inhaled by male Wistar rats. Toxicology 42: 219-232.
15. Gordon E. 2007. Captan: transition from 'B2' to 'not likely'. How pesticide registrants affected the EPA Cancer Classification Update. J. Appl. Toxicol. 27: 519-526.
16. Grady WM, Carethers JM. 2008. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135: 1079-1099.
17. Greaves P. 2012. Histopathology of Preclinical Toxicity Studies, 4th edn. Elsevier-Academic Press: London.
18. IARC. 1990. Chromium, nickel and welding. IARC Monogr. Eval. Carcinog. Risks Hum. 49: 1-648.
19. ICRP. 2002. Basic anatomical and physiological data for use in radiological protection: reference values. internation commision on radiological protection ICRP Publication, 89.
20. Kirman CR, Hays SM, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem. Biol. Interact. 200: 45-64.
21. Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Parker W, Lin S, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem. Biol. Interac 204: 13-27.
22. Kopec AK, Kim S, Forgacs AL, Zacharewski TR, Proctor DM, Harris MA, Haws LC, Thompson CM. 2012a. Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia following 7 and 90days of exposure to hexavalent chromium in drinking water. Toxicol. Appl. Pharmacol. 259: 13-26.
23. Kopec AK, Thompson CM, Kim S, Forgacs AL, Zacharewski TR. 2012b. Comparative toxicogenomic analysis of oral Cr(VI) exposure effects in rat and mouse small intestinal epithelia. Toxicol. Appl. Pharmacol. 262: 124-138.
24. NTP. 2007. National Toxicology Program Technical Report on the Toxicity Studies of Sodium Dichromate Dihydrate (CAS No. 7789-12-0) Administered in Drinking Water to Male and Female F344/N Rats and B6C3F1 Mice and Male BALB/c and am3-C57BL/6 mice. NTP Toxicity Report Series No. 72, NIH Publication No. 07-5964.
25. NTP. 2008a. National Toxicology Program Technical Report on the Toxicology and Carcinogenesis Studies of Chromium Picolinate Monohydrate (CAS NO. 27882-76-4) in F344/N Rats and B6C3F1 Mice (Feed Studies). NIH Publication No. 08-5897.
26. NTP. 2008b. National Toxicology Program Technical Report on the Toxicology and Carcinogenesis Studies of Sodium Dichromate Dihydrate (CAS No. 7789-12-0) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies), NTP TR 546. NIH Publication No. 08-5887.
27. O'Brien TJ, Ding H, Suh M, Thompson CM, Parsons BL, Harris MA, Winkelman WA, Wolf JC, Hixon JG, Schwartz AM, Myers MB, Haws LC, Proctor DM. 2013. Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water. Mutat. Res. 754(1-2): 15-21.
28. Parsons BL, Manjanath MB, Myers, MB, McKim KL, Wang Y, Gollapudi BB, Moore N, Haber LT, Moore MM. 2012. Induction of cII and K-Ras mutation in lung DNA of Big Blue mice exposed to ethylene oxide by inhalation). Bellevue: Washington.
29. Proctor DM, Otani JM, Finley BL, Paustenbach DJ, Bland JA, Speizer N, Sargent EV. 2002. Is hexavalent chromium carcinogenic via ingestion? A weight-of-evidence review. J. Toxicol. Environ. Health A 65: 701-746.
30. Proctor DM, Suh M, Aylward LL, Kirman CR, Harris MA, Thompson CM, Gurleyuk H, Gerads R, Haws LC, Hays SM. 2012. Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere 89: 487-493.
31. Steinhoff D, Gad SC, Hatfield GK, Mohr U. 1986. Carcinogenicity study with sodium dichromate in rats. Exp. Pathol. 30: 129-141.
32. Stout MD, Herbert RA, Kissling GE, Collins BJ, Travlos GS, Witt KL, Melnick RL, Abdo KM, Malarkey DE, Hooth MJ. 2009. Hexavalent chromium is carcinogenic to F344/N rats and B6C3F1 mice after chronic oral exposure. Environ. Health Perspect. 117: 716-722.
33. Thompson CM, Haws LC, Harris MA, Gatto NM, Proctor DM. 2011a. Application of the US EPA mode of action Framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromium. Toxicol. Sci. 119: 20-40.
34. Thompson CM, Proctor DM, Haws LC, Hebert CD, Grimes SD, Shertzer HG, Kopec AK, Hixon JG, Zacharewski TR, Harris MA. 2011b. Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium. Toxicol. Sci. 123: 58-70.
35. Thompson CM, Fedorov YD, Brown DD, Suh M, Proctor DM, Kuriakose L, Haws LC, Harris MA. 2012a. Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis. PLoS One 7: e42720.
36. Thompson CM, Gregory Hixon J, Proctor DM, Haws LC, Suh M, Urban JD, Harris MA. 2012b. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: An in silico comparison with mutagenic and nonmutagenic carcinogens across tissues. Regul. Toxicol. Pharmacol. 64: 68-76.
37. Thompson CM, Proctor DM, Suh M, Haws LC, Hebert CD, Mann JF, Shertzer HG, Hixon JG, Harris MA. 2012c. Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: implications for carcinogenic modes of action. Toxicol. Sci. 125: 79-90.
38. Thompson CM, Proctor DM, Suh M, Haws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Crit. Rev. Toxicol. 43: 244-274.
39. US EPA. 2004. Captan; cancer reclassification; amendment of reregistration eligibility decision; notice of availability. Fed. Regist. 69: 68357-68360.
40. US EPA. 2005. Guidelines for carcinogen risk assessment, EPA/630/P-03/001F. Risk Assessment Forum: US Environmental Protection Agency: Washington, DC.
41. US EPA. 2006. Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment. US Environmental Protection Agency: Washington, D.C.
42. US EPA. 2010. Toxicological review of hexavalent chromium in support of summary information on the integrated risk information system (IRIS). External Review DRAFT. US Environmental Protection Agency: Washington, DC.
43. US EPA. 2011. Recommended Use of Body Weight 3/4 as the Default Method in Derivation of the Oral Reference Dose. Risk Assessment Forum: Washington, DC.
44. US EPA. 2012. Benchmark Dose Technical Guidance. Risk Assessment Forum, U.S. Environmental Protection Agency: Washington, DC.